A name from the market, not the literature
GLP-1 and GLP-2 are real things: two peptides derived from the same precursor, each with its own receptor. GLP-3 does not follow that pattern. It appeared as a commercial label, and the numbering implies a sequence in a family that does not extend that far.
What suppliers generally mean by it is triple-agonist material, in the same class as retatrutide: a single molecule engineered to act at GLP-1, GIP and glucagon receptors together. If that is what you are after, the honest question to ask any supplier is which compound the label refers to and what the certificate of analysis identifies it as.
Two questions sit inside a search for what is GLP-3: what the label points at, and whether the material behind it is worth studying. The numbering also invites a third, mistaken assumption, a GLP-3 receptor sitting next in sequence, which is the part to discard first.
What triple agonism actually means
A single-molecule triple agonist is a design choice rather than a strength ranking. Putting three receptor activities into one backbone lets researchers compare combinations inside one construct instead of dosing three separate substances and trying to untangle the result afterwards.
Because the activity is spread across three routes, the published work profiles each arm separately before saying anything about the combination. The relative potency at each receptor is treated as a defining property of the molecule, not a footnote.
The class this label gestures at is easier to grasp through a molecule that carries a formal name. The file on the dual GIP and GLP-1 agonist tirzepatide shows how each receptor arm is profiled separately before any combined claim, and the same discipline applies to whatever a triple agonist is sold as here.
| Common name | GLP-3 |
| Formal name | None, market designation |
| Class | Triple receptor agonist |
| Receptors | GLP-1, GIP, glucagon |
| Format | Pre-filled peptide pen |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Receptor assays and animal pharmacology |
| Category | Research use only |
Research context only. Nothing in this table describes an effect in a person.
Why the label matters to you
A product name that does not map to a compound name makes verification harder. You cannot look up "GLP-3" in a database, which means the only way to know what you have is the identity confirmation on the certificate for your batch.
That is not a reason to avoid the material. It is a reason to insist on the certificate before ordering, and to check that the compound it names is one you can actually find literature on.
What that leaves is a question for the seller rather than for a database: which compound was identified in this batch, and by which method. You can still read the wider work on incretin co-agonists through the results indexed on PubMed, but for the specific pen in front of you the certificate of analysis is the one document that settles identity.
Where a market name meets the metabolic research
Most enquiries about this label arrive from the metabolic corner of the field, where single molecules acting at several incretin receptors are the current focus. The framing to keep is that the interest is genuine and the naming is not: the science belongs to well-described receptors, while the product name is a shorthand the market settled on.
If you are surveying that whole area rather than one product, the overview of the weight and metabolic research area gives the map, and the catalogue of what is stocked shows what sits behind the shelf labels. Neither changes the rule that the certificate, not the name, tells you what you hold.
GLP-3 in the catalogue
Released at 99% or higher by HPLC, with the certificate available per batch.
Where GLP-3 fits in
Three pages that put this compound in context.
About GLP-3
The questions we get most often about this compound.